A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDl3280A (Anti−PD-L1 Antibody) In Combination with Carboplatin and Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer

[Abbreviated - Closed] The purpose of this study is to look at the effects, good or bad, of MPDL3280A on you and the specific type of lung cancer (non−small cell lung cancer [NSCLC]) from which you are suffering. MPDL3280A is an experimental drug, which means that health authorities have not approved MPDL3280A for the treatment of NSCLC. You were selected as a possible participant in this study because you have a tumor that has spread to areas near your lungs or other organs and has not yet been treated by prior chemotherapy.